Clinical Trials Logo

Clinical Trial Summary

Spontaneous pregnancy loss is a relatively common phenomenon, with 10-15% of clinically recognized pregnancies ending in miscarriage.1 Recurrent pregnancy loss (RPL) is a disorder defined by two or more failed pregnancies2. According to various studies, pregnancy loss has been described as a traumatic event for couples even if the loss occurs at a very early stage of pregnancy. Few controlled studies dealt with the effects of the miscarriage on the psychological condition of women during a subsequent pregnancy, 4,6-8. This study aimed to evaluate the effectiveness of "at home ultrasound" in addition to routine prenatal care in reducing maternal anxiety during pregnancy for patients with history of recurrent pregnancy loss. i. Inclusion criteria: 1. Patients with recurrent pregnancy losses in first trimester 2. Current pregnancy gestational age 12-14 week of gestation 3. Singleton pregnancy ii. Exclusion criteria: 1. Female subjects who refuse to participate 2. Female subjects who don't speak Hebrew Device details: Pulsenmore Specifications: Compatible with: Android mobile phones with USB type C connector (Samsung S8+, Nokia 8, Nokia 7.1) ApplicatThe aim of this study is to evaluate the effectiveness of "at home ultrasound" in addition to routine prenatal care in reducing maternal anxiety during pregnancy for patients with history of recurrent pregnancy loss.ion: PulseNmore ES™, downloadable from Google Play™ Store.


Clinical Trial Description

Background: Spontaneous pregnancy loss is a relatively common phenomenon, with 10-15% of clinically recognized pregnancies ending in miscarriage.1 Recurrent pregnancy loss (RPL) is a disorder defined by two or more failed pregnancies2. According to various studies, pregnancy loss has been described as a traumatic event for couples even if the loss occurs at a very early stage of pregnancy.3-5 Few controlled studies dealt with the effects of the miscarriage on the psychological condition of women during a subsequent pregnancy4,6-8. These studies establish proof of considerably increased pregnancy specific anxiety in pregnant women with a history of spontaneous abortion, compared to pregnant women with no history of spontaneous abortion. As in the study of Bergner et al. women after early miscarriages are under pressure in a new pregnancy due to emotional disorders in the shape of pregnancy-specific anxiety, mostly before the critical point in the pregnancy when the previous miscarriage took place is passed.6 In order to offer pregnant women who have previously suffered miscarriages, apart from adequate psychological support alongside workup to find the RPL etiology, some reassurance and comfort this study aimed to evaluate the effectiveness of "at home ultrasound" in addition to routine prenatal care in reducing maternal anxiety during pregnancy for patients with history of recurrent pregnancy loss. Study primary objectives/hypotheses: Of all interventions that can alleviate the stress during pregnancy, we wish to learn the effect of "at home ultrasound" used by patients and feedback by clinician. The aim of this study is to evaluate the effectiveness of "at home ultrasound" in addition to routine prenatal care in reducing maternal anxiety during pregnancy for patients with history of recurrent pregnancy loss. We hypothesize that couples would feel calmer and more reassured regarding their pregnancy. Administrative Organization: Department of Obstetrics and Gynecology at the Edith Wolfson Medical Center, Holon, Israel. Study population The study population includes gravid patients recruited between 12 weeks of gestation and 14 weeks. Eligible patients include women with recurrent pregnancy losses in first trimester. This is a randomized controlled prospective trial registered at TRIALS.GOV The study population will be recruited between 12 and 14 weeks of gestation. The study population will be subject to standard routine antenatal care per clinic protocol. In addition, these patients will be followed using a twice weekly virtual visit by a member of the study team. This visit will include a short survey of obstetrical complaints such as abdominal pain and vaginal bleeding, as well as a brief sonographic survey using the portable ultrasound device. The details and findings of the visit will be recorded in the medical charts. The portable device will be handed to the patient during the intake visit of the study. The patient will be instructed how to operate the device by a team member. Pulsenmore Specifications: Compatible with: Android mobile phones with USB type C connector (Samsung S8+, Nokia 8, Nokia 7.1) Application: PulseNmore ES™, downloadable from Google Play™ Store Network Connectivity: Wi-Fi or cellular (via user's mobile phone) Data Upload: Secured cloud service compliant with formal information security standards and directives Probes used only for external use on intact skin without contamination of blood or bodily fluids and should be cleaned with low-level disinfection between each use and sterilized prior patient exchange according to our departmental protocol. The control group: A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention. i. Inclusion criteria: 1. Patients with recurrent pregnancy losses in first trimester 2. Current pregnancy gestational age 12-14 week of gestation 3. Singleton pregnancy ii. Exclusion criteria: 1. Female subjects who refuse to participate 2. Female subjects who don't speak Hebrew Methods: 1. Recruitment of eligible patients will be conducted during routine visits to the maternal fetal outpatient clinic. Patients will receive an explanation of the study protocol, purpose and methodology including the difference between the two study groups. Willing participants will sign an informed consent. 2. At the initiation visit, the patient will be randomly assigned to one of the two study groups. 3. Following the random assignment, all participants will complete 3 validated questionnaires. The first questionnaire, validated to a state of acute anxiety, termed STAI:Y-1, The State-Trait Anxiety Inventory. This version, includes 20 items representing anxiety related sensations. Patients will be instructed to scale on a range of 1 to 4, where 1 stands for strongly disagree and 4 for strongly agree, how do each of the items represent the current state of anxiety. The final grade for each questionnaire is obtained through summing all ranks. The scale is reversed for each item phrased in a positive note before summation. A higher grade correlates with greater anxiety. Addendum 1. The second questionnaire validated to the evaluation of maternal attachment to the fetus during pregnancy until the week of recruitment to the study. The questionnaire is termed: Maternal Antenatal Attachment Scale-MAAS (female) Addendum 2. The third questionnaire, validated to evaluate the overall pregnancy experience: Revised Prenatal Distress Questionnaire (NUPDQ; Lobel et al., 2008) Addendum 3. After completion of the questionnaires, the patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team. The patient will receive a written manual of operation for the device and will sign a contract obligating to preserve and return the device at the end of the study period. 4. At 20-22 weeks of gestation, the participants will complete again all the three questionnaires. During that visit, the patient will return the device to the present team member. 5. Collected data includes: 1. Demographic characteristics (age, BMI, smoking, number of pregnancies, number of deliveries, past obstetrical and medical history, use of medication) 2. Antenatal follow-up 3. The results of the various questionnaires primary outcome The delta between The State-Trait Anxiety Inventory (STAI:Y-1) score filled at recruitment and at 20-22 weeks of gestation (when patient start fill fetal movements). Secondary outcomes The delta between The Maternal Antenatal Attachment Scale MAAS and the Distress Questionnaire score filled at recruitment and at 20-22 weeks of gestation. Number of obstetric ICU referrals Number of admissions for hospitalization during pregnancy Sample size For the purpose of calculating the sample size, suppose that The State-Trait Anxiety Inventory (STAI: Y-1) at the second trimester for a patient with reccurent pregnancy losses is 40 units with a standard deviation of 5 units based on previous work. 9 to demonstrate a decrease in the score) The State-Trait Anxiety Inventory (STAI: Y-1) in 8 units will need to recruit 50 women (25 per group) with 80 percent power and 0.05 alpha. Research funding - The authors will not receive any financial support for the research. The devices are provided as a contribution for the research period by the Pulsenmore Company Study Duration - 1 year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05656846
Study type Interventional
Source Wolfson Medical Center
Contact Michal Levi, Dr.
Phone 0528591994
Email levmichal@gmail.com
Status Recruiting
Phase N/A
Start date July 15, 2022
Completion date April 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT04718233 - Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss Phase 2
Recruiting NCT01946945 - Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis Phase 2
Completed NCT02572154 - Sperm DNA Fragmentation in Recurrent Pregnancy Loss N/A
Completed NCT03174951 - Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Phase 2
Recruiting NCT05444283 - Genomic Predictors of Recurrent Pregnancy Loss
Active, not recruiting NCT04621773 - Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
Recruiting NCT02990403 - The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss Phase 4
Recruiting NCT02990390 - The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla N/A
Not yet recruiting NCT05612620 - Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05520112 - Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells Phase 1/Phase 2
Suspended NCT04397042 - SCUBE-1 and Carotid Intima Media Thickness in Recurrent Pregnancy Loss
Not yet recruiting NCT05341856 - Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL Early Phase 1
Recruiting NCT06007560 - Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss N/A
Completed NCT02386384 - TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure N/A
Recruiting NCT01635426 - Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages Phase 2/Phase 3
Suspended NCT01546350 - Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH Phase 2
Completed NCT00721591 - Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy N/A
Terminated NCT00564174 - Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT N/A
Completed NCT04455256 - Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05237843 - Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss Phase 1